Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Jun 7, 2011

Premium

Frank Witney has been named president and CEO of Affymetrix, taking over for Kevin King, who left. Witney also will serve on the company's board of directors.

Witney was previously executive VP and chief commercial officer for Affymetrix, and for the past two years CEO and president of Dionex, which was recently bought by Thermo Fisher Scientific. He was president and CEO of Panomics before the company was acquired by Affymetrix, president and COO at Packard BioScience, and president of drug discovery tools at PerkinElmer Life Sciences after it acquired Packard.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.